CTIS2024-514224-17-00进行中(未招募)1 期
Ticagrelor monotherapy after coronary stenting in patients with acute myocardial infarction - A prospective single-centre, single-arm phase II study - 5.1
Vaestra Goetalandsregionen0 个研究点目标入组 200 人开始时间: 2024年5月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Men or women at least 18 years old., Pre- or intra-procedure treatment with ticagrelor., Coronary stenting with an everolimus-eluting stent (EES) due to NSTEMI or STEMI, with post-procedure diameter stenosis <50% and post-procedure Thrombolysis In Myocardial Infarcton (TIMI) flow grade 3., Subject has not yet received any post-procedure dose of aspirin or any post-procedure dose of a different P2Y12 inhibitor than ticagrelor (loading dose or pre-PCI maintenance dose of aspirin and/or a different P2Y12 inhibitor is allowed)., Subject has signed and dated the informed consent form.
排除标准
- •Planned PCI or any planned surgical intervention within the next 6 months., Any treated lesion within an arterial or venous graft., Any additional lesion(s) that need(s) a staged revascularization., Known ejection fraction <30%., Known severe renal insufficiency (eGFR <30 ml/min/1.72 m2)., Any life-threatening conditions or medical comorbidity resulting in life expectancy < 12 months., Participation in any investigational study that has not yet reached its primary endpoint, and for which monotherapy with ticagrelor may affect the primary outcome (as per the judgement of the investigator)., Patients who medicate with a potent CYP3A4 inhibitor (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir), Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception., Expected inability (by the investigator) to comply with the protocol, Subjects incapable to giving consent personally, Any indication for chronic anticoagulant therapy., Positive COVID-19 antigen or PCR test regardless of symptoms., History of definite stent thrombosis., Left main coronary artery stenting., Stent thrombosis/restenosis as a culprit lesion., Visible thrombus on angiography after PCI., Usage of glycoprotein IIb/IIIa inhibitors., Any bifurcation lesion with stenting of both branches.
研究者
相似试验
招募中
2 期
Ticagrelor monotherapy after coronary stenting in patients with acute myocardial infarction - A prospective single-centre, single-arm phase II studyMyocardial infarction2024-514224-17-00Vaestra Goetalandsregionen, Vaestra Goetalandsregionen200
进行中(未招募)
2 期
Ticagrelor Monotherapy After StentingAcute Myocardial InfarctionNCT05149560Vastra Gotaland Region200
终止
4 期
Anti-anginal Efficacy of Ticagrelor in Coronary Slow Flow.Coronary Slow Flow PhenomenonCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12616000388415niversity of Adelaide24
招募中
不适用
The safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhageST-elevation myocardial infarctionheart attack10011082NL-OMON56396Academisch Medisch Centrum200
招募中
不适用
Ticagrelor monotherapy in PAtients treated with new-generation drug-eluting Stents for acute coronary Syndrome; T-PASS trialDiseases of the circulatory systemKCT0003744Yonsei University Health System, Severance Hospital2,850
